NCT05159895已完成1 期
A Phase 1, Single-Center, Nonrandomized, Open-label Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects
Dizal Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2021年9月24日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Percentage of Total Radioactivity (Cum% Dose) Recovered in Urine Relative to the Administered Radioactive Dose
研究概览
简要总结
This is a phase 1, open-label, ADME study with single oral administration of [14C]-DZD9008 in healthy subjects.
详细描述
Phase 1 study to evaluate the excretion of DZD9008 radioactive dose, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]-DZD9008 in healthy male subjects. The purpose of this study is to investigate ADME properties of DZD9008 by analyzing blood, urine and feces samples collected during the study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects between 18 and 60 years of age, with body mass index of 18.0 to 30.0 kg/m
- •Body weight: ≥55 kg,and ≤ 100 kg.
- •In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, clinical laboratory evaluations.
- •Regular bowel movements (ie, average production of ≥ 1 or ≤ 3 bowel movements a day).
- •Adhere to specific contraception requirements
- •Creatinine clearance ≥ 90 mL/min/1.73 m
- •Aspartate aminotransferase and alanine aminotransferase must be ≤2.5 × upper limit of normal (ULN) and total bilirubin ≤1.5 × ULN.
排除标准
- •Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, respiratory, endocrine, or psychiatric disorder.
- •History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator, or history of hypersensitivity to DZD9008, its excipients, or drugs with a similar chemical structure or class.
- •History of stomach or intestinal surgery history or presence of hepatic or renal disease or surgical procedure that would potentially alter absorption and/or excretion of orally-administered drugs (uncomplicated appendectomy and hernia repair will be allowed; cholecystectomy will not be allowed).
- •Any clinically significant abnormalities in physical examination performed at check-in, vital signs (supine systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, and pulse rate ≥100 or ≤35 beats per minute) or clinical laboratory evaluations as judged by the investigator (or designee).
- •Any clinically important abnormalities in rhythm, conduction, or morphology of resting 12-lead ECG, QTcF interval >450 msec, as judged by the investigator (or designee).
- •A history of additional risk factors for Torsades de pointes (eg, heart failure, hypokalemia, family history of Long QT syndrome).
- •Positive/reactive results on screening tests for serum hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (Appendix 2).
- •Acute illness, surgical procedures or trauma from within 2 weeks before screening until the first administration of the IMP.
- •Subjects with active malignancy or neoplastic disease in the previous 12 months.
- •Ongoing or planned inpatient surgery, dental procedure, or hospitalization during the study.
- •Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 30 days prior to dosing.
- •Use or intend to use any medications/products known to alter drug AME processes, including St. John's wort, within 30 days prior to check-in, unless deemed acceptable by the investigator (or designee).
- •Use or intend to use any prescription medications/products within 28 days prior to check-in, unless deemed acceptable by the investigator (or designee). Exceptions may be allowed on a case by case basis as agreed by the investigator and sponsor's medical monitor if considered not to interfere with the aims of the study.
- •Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee).
- •Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations, gastric pH modifiers, and neutralizing antacids within 7 days prior to check-in, unless deemed acceptable by the investigator (or designee).
- •Subjects will avoid the use of any prescription or nonprescription medications/products or herbal remedies that are strong/moderate CYP3A inhibitors or inducers within 28 days prior to check-in through the end of study, unless deemed acceptable by the Investigator.
- •Subjects will avoid the use of any prescription or nonprescription medications/products or herbal remedies that are transporter (eg, P-gp) inhibitors or inducers within 28 days prior to the check-in through the end of study, unless deemed acceptable by the Investigator.
- •Subjects should avoid the use of proton pump inhibitors from 7 days prior to check-in through 5 days postdose. For H2-antagonists or antacids, administration will follow the staggered schedule per protocol.
- •Subjects who received a live or live-attenuated vaccine in the 2 weeks prior to IMP administration.
- •Participation in a clinical study involving administration of an investigational drug (new chemical entity defined as a compound which has not been approved for marketing) or participation in any other clinical study (including methodology studies where no drugs were given) in the past 90 days prior to dosing.
- •Subjects who have participated in any radiolabeled drug studies in the last 12 months prior to check-in.
- •Have previously completed or withdrawn from this study or any other study investigating DZD9008 and have previously received DZD
- •History of alcohol abuse or excessive alcohol consumption, defined as > 21 units per week for males. One unit of alcohol equals 8.5 oz (250 mL) beer, 0.85 oz (25 mL) liquor, or 2.4 oz (125 mL) wine.
- •Positive urine drug detected at screening, positive urinary alcohol test result or positive urine drug detected at check-in.
- •History or suspected history of alcoholism or drug/chemical abuse within 2 years prior to check-in, as judged by the investigator (or designee).
- •Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.
- •Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to check-in.
- •Receipt of blood products within 2 months prior to check-in.
- •Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, platelets from 6 weeks prior to screening, or any blood loss greater than 500 mL during the 3 months prior to screening.
- •Poor peripheral venous access.
研究组 & 干预措施
[14C]-DZD9008
Experimental
A Single dose of [14C]-DZD9008
干预措施: [14C]-DZD9008 (Drug)
结局指标
主要结局
Percentage of Total Radioactivity (Cum% Dose) Recovered in Urine Relative to the Administered Radioactive Dose
时间窗: Up to 85 days
Percentage of Administered Radioactive Dose (%Dose) Excreted in Feces for [14C]-DZD9008
时间窗: Up to 85 days
Percentage of Total Radioactivity (Cum% Dose) Recovered in Feces Relative to the Administered Radioactive Dose
时间窗: Up to 85 days
Amount of Total Radioactivity Excreted in Feces (Ae [Fe])
时间窗: Up to 85 days
Percentage of Administered Radioactive Dose (%Dose) Excreted in Urine for [14C]-DZD9008
时间窗: Up to 85 days
Amount of Total Radioactivity Excreted in Urine (Ae [UR])
时间窗: Up to 85 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
DZD9008 PK Study in Hepatic Impairment SubjectsHepatic ImpairmentNCT06084104Dizal Pharmaceuticals17
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914Gonococcal (GC) InfectionNCT01929629AstraZeneca100
已完成
1 期
Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male VolunteersHealthy VolunteersNCT04225208Dizal Pharmaceuticals8
已完成
1 期
AZD8529 Multiple Ascending Dose Study in Healthy SubjectsHealthy VolunteerNCT00765492AstraZeneca47
终止
1 期
A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy MalesHealthy SubjectsNCT02072993AstraZeneca116